Company Profile
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company develops novel therapeutics for transformative diseases globally. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection.
Its portfolio also includes TG-1000, which is in phase III clinical trial to treat influenza A and B, TG-4318, ISM-4808 to treat CKD anemia, Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C, and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization Consultation on pharmaceutical technology; and manufacture and sale of health food. Founded in 2001, the company is based in Taipei City, Taiwan.